Live
- BJP Leaders Summoned By Bengaluru Police Over Controversial Social Media Post
- Sensex, Nifty end flat after another volatile session
- Punjab: Congress candidates Khaira, Gandhi file nominations
- BMW earnings hit by model change, lower profits on e-auto sales
- 3 police officers killed, 5 injured in blast in Afghanistan
- OpenAI Introduces New Tools for Detecting DALL-E 3 Generated Images
- Forty years on, still no rail line
- Live Update: YSRCP govt. betrayed people of AP, slams PM Modi
- Gusty winds, rains lash Karimnagar
- TDP to support BJP in Khammam
Natco Pharma bullish on India, Brazil, Canada biz for FY20 growth
Natco Pharma expects India, Brazil and Canada markets to be its revenue drivers during the current financial year, recording growth of 30 per cent to 40 per cent, according to a top company executive.
Hyderabad: Natco Pharma expects India, Brazil and Canada markets to be its revenue drivers during the current financial year, recording growth of 30 per cent to 40 per cent, according to a top company executive.
The India business alone was likely to grow by about 15 per cent to 20 per cent, Natco Vice-Chairman and Chief Executive Officer Rajeev Nannapaneni has said."The second driver will be Brazil.
Brazil did not do well for many years, so we had some very good launches this year and so that should drive earnings," he said replying to a query during a recently held Earnings Call of the company.
Talking about Canada, he said Natco was anticipating a couple of launches and a couple of "favourable settlements".
If they all come through, the city-based drug maker expected the three markets to grow at 30 per cent to 40 per cent, he added.
India is expecting about eight to 10 launches this year. Brazil we are expecting about three to four launches.
